< Back

CUTISS launches Series C financing round to advance the development of its personalized skin technology

CUTISS seeks to raise the Series C with the participation of existing and new investors to take its personalized skin therapy denovoSkin™ into the final stages of development, having recently completed the recruitment in Phase 2 clinical trials with positive results.